749905-01-9Relevant academic research and scientific papers
Therapeutic combinations
-
Page/Page column 16-17, (2010/02/13)
The present invention relates to methods for improving the pharmacokinetics of certain compounds useful as inhibitors of the HIV protease enzyme by inhibiting the enzyme activity of cytochrome P450. The present invention also relates to compositions compr
COMPOSITIONS COMPRISING AN HIV PROTEASE INHIBITOR
-
Page/Page column 58-60, (2010/02/12)
The present invention relates to pharmaceutical compositions comprising amorphous (4R)-N-allyl-3-{(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide, or a pharmaceutically acceptable salt o
Therapeutic combinations
-
Page/Page column 16, (2010/02/13)
The present invention relates to methods for treating an HIV infection a mammal by administering to the mammal a therapeutically effective amount of a combination of compounds. The present invention also relates to compositions comprising certain compound
Methods of preparing compounds useful as protease inhibitors
-
Page/Page column 30-31, (2010/02/11)
The invention relates to methods of preparing compounds of formula (I), useful as inhibitors of the HIV protease enzyme. The present invention also relates to intermediate compounds useful in the preparation of compounds of formula (I).
METHODS OF PREPARING COMPOUNDS USEFUL AS PROTEASE INHIBITORS
-
Page/Page column 79-80, (2010/02/12)
The invention relates to methods of preparing compounds of formula (I) that are useful as inhibitors of the HIV protease enzyme. The present invention also relates to intermediate compounds useful in the preparation of compounds of formula (I).
